Abstract Library

#3888 Outcome of typical and atypical carcinoids after surgical resection – A single center retrospective study

Introduction: Typical (TC) and atypical carcinoids (AC) are rare malignant neoplasms.

Conference:

Presenting Author: Rubino M

Authors: Rubino M, Girelli L, Pisa E, Gervaso L, Spada F,

Keywords: lung carcinoid, primary surgery, recurrence rate, overall survival,

#3846 Poorly differentiated neuroendocrine carcinomas – Characteristics, treatments and outcomes from a population-based cohort discussed in our ENETS-CoE institute

Introduction: Poorly differentiated neuroendocrine carcinomas (NECs) are rare malignancies with a dismal prognosis, few therapeutic options available and lacking predictive factors.

Conference:

Presenting Author: Benini L

Authors: Benini L, Spada F, Gervaso L, Borghesani M, Rubino M,

Keywords: Neuroendocrine Carcinoma, NEC,

#3821 Risk of venous thromboembolism in pancreatic neuroendocrine neoplasms

Introduction: Venous thromboembolism (VTE) is a leading cause of morbidity and death in cancer. The incidence of VTE is increased in different cancers such as pancreatic ductal adenocarcinoma, however limited evidence is present this risk for pancreatic neuroendocrine neoplasms (pan-NENs).

Conference:

Presenting Author: Gervaso L

Authors: Gervaso L, Laffi A, Cella C, Rubino M, Spada F,

Keywords: Venous thromboembolism, pancreatic neuroendocrine tumor, pancreatic neuroendocrine carcinoma, NEN, VTE,

#3478 Peptide Receptor Radionuclide Therapy with 177Lutethium or 90Yttrium- DOTA-TATE or –TOC in Malignant Pheochromocytomas (PCCs) and Paragangliomas (PGLs): Results from a single institutional retrospective analysis

Introduction: Malignant pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare tumors and limited systemic therapies are available so far.

Conference:

Presenting Author: Rubino M

Authors: Rubino M, Di Stasio G, Spada F, Rocca P, Laffi A,

Keywords: Pheochromocytoma, Paraganglioma, Peptide Receptor Radionuclide Therapy, 90Y, 177Lu,

#3128 An unexpected effect of chronic treatment with Temozolomide in patients with metastatic, well-differentiated neuroendocrine tumors

Introduction: Temozolomide (TEM) is an alkylating agent indicated for several neoplasms treatment, as neuroendocrine tumors (NETs). Myelosuppression is the most common adverse event (AE).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Laffi A, Nicosia L, Spada F, Rubino M, Fazio N,

Keywords: NET, neuroendocrine, temozolomide, gynecomastia, breast,